Beximco Pharmaceuticals (LSE:BXP) Cyclically Adjusted Revenue per Share: £0.32 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:BXP Beximco Pharmaceuticals PLC LSE:BXP
71 GF Score
Price £0.52
GF Value £0.49
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Beximco Pharmaceuticals Cyclically Adjusted Revenue per Share?

Beximco Pharmaceuticals LSE:BXP -1.89% 71 Cyclically Adjusted Revenue per Share is £0.32 as of Mar. 2026. GuruFocus rates LSE:BXP with a GF Score™ of 71/100 and a GF Value™ of £0.49 (Fairly Valued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Beximco Pharmaceuticals's adjusted revenue per share for the three months ended in Mar. 2026 was £0.186. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is £0.32 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Beximco Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 14.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 15.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 16.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Beximco Pharmaceuticals was 17.80% per year. The lowest was 13.70% per year. And the median was 17.40% per year.

As of today (2026-07-24), Beximco Pharmaceuticals's current stock price is £0.52. Beximco Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was £0.32. Beximco Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 1.63.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Beximco Pharmaceuticals was 6.04. The lowest was 0.98. And the median was 2.53.


Beximco Pharmaceuticals  (LSE:BXP) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Beximco Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.52/0.32
=1.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Beximco Pharmaceuticals was 6.04. The lowest was 0.98. And the median was 2.53.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Beximco Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


Beximco Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Beximco Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beximco Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Beximco Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.20 0.23 0.14 0.22 0.32

Beximco Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 0.32 0.30 0.34 0.32

LSE:BXP vs ZTS, UTHR: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Beximco Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beximco Pharmaceuticals Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beximco Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Beximco Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


LSE:BXP
71GF Score
Beximco Pharmaceuticals PLC LSE:BXP
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beximco Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Beximco Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.186/330.2130*330.2130
=0.186

Current CPI (Mar. 2026) = 330.2130.

Beximco Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.000 241.018 0.000
201609 0.054 241.428 0.074
201612 0.053 241.432 0.072
201703 0.052 243.801 0.070
201706 0.055 244.955 0.074
201709 0.058 246.819 0.078
201712 0.059 246.524 0.079
201803 0.058 249.554 0.077
201806 0.066 251.989 0.086
201809 0.073 252.439 0.095
201812 0.078 251.233 0.103
201903 0.078 254.202 0.101
201906 0.081 256.143 0.104
201909 0.078 256.759 0.100
201912 0.084 256.974 0.108
202003 0.090 258.115 0.115
202006 0.089 257.797 0.114
202009 0.094 260.280 0.119
202012 0.102 260.474 0.129
202103 0.100 264.877 0.125
202106 0.105 271.696 0.128
202109 0.115 274.310 0.138
202112 0.116 278.802 0.137
202203 0.122 287.504 0.140
202206 0.119 296.311 0.133
202209 0.133 296.808 0.148
202212 0.135 296.797 0.150
202303 0.130 301.836 0.142
202306 0.137 305.109 0.148
202309 0.152 307.789 0.163
202312 0.149 306.746 0.160
202403 0.150 312.332 0.159
202406 0.155 314.175 0.163
202409 0.160 315.301 0.168
202412 0.168 315.605 0.176
202503 0.172 319.799 0.178
202506 0.170 322.561 0.174
202509 0.188 324.800 0.191
202512 0.191 324.054 0.195
202603 0.186 330.213 0.186

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of £0.32 mean?
Beximco Pharmaceuticals (LSE:BXP) has a Cyclically Adjusted Revenue per Share of £0.32 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Beximco Pharmaceuticals and its competitors.
Is Beximco Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
Beximco Pharmaceuticals' current Cyclically Adjusted Revenue per Share is £0.32. Overall, Beximco Pharmaceuticals has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Beximco Pharmaceuticals' Cyclically Adjusted Revenue per Share of £0.32 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Beximco Pharmaceuticals and its competitors. Beximco Pharmaceuticals's current Cyclically Adjusted Revenue per Share is £0.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Beximco Pharmaceuticals (LSE:BXP) is currently considered Fairly Valued. The stock's GF Value™ is £0.49, compared to a current price of £0.52 — trading 6.1% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is £0.32. Beximco Pharmaceuticals' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Beximco Pharmaceuticals (LSE:BXP), the current Cyclically Adjusted Revenue per Share is £0.32 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beximco Pharmaceuticals (LSE:BXP) Overvalued in 2026?

Based on GuruFocus' analysis, Beximco Pharmaceuticals stock appears to be overvalued. The current stock price of £0.52 is trading 6.1% above its estimated GF Value™ of £0.49. GuruFocus considers Beximco Pharmaceuticals to be Fairly Valued.

Key valuation signals for LSE:BXP:

  • Cyclically Adjusted Revenue per Share: £0.32
  • GF Value™: £0.49 vs. price of £0.52 (6.1% above fair value)
  • GF Score™: 71/100 with 5 warning signs

No single metric tells the full story. See the LSE:BXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Beximco Pharmaceuticals Business Description

Address 19 Dhanmondi, Road No. 7, Dhaka, BGD, 1205
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.
71GF Score

Get the complete analysis for LSE:BXP

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.52
Price
£0.49
GF Value